Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Rituximab 45Cyclophosphamide 32fludarabine phosphate 28fludarabine 19ibrutinib 17Peripheral Blood Stem Cell Transplantation 17Lenalidomide 17venetoclax 13Mycophenolic Acid 10Cyclosporine 10acalabrutinib 9Whole-Body Irradiation 9Filgrastim 9obinutuzumab 7Bendamustine Hydrochloride 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Melphalan 6Prednisone 5Etoposide 5Busulfan 5zanubrutinib 4pirtobrutinib 4aldesleukin 4Vincristine 4Tacrolimus 4Indium 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × navitoclax × Clear all
NCT00481091 2023-06-13

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

AbbVie

Phase 1/2 Completed
60 enrolled 32 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡